| Source publication date | |
|---|---|
| Reported on Testosterone Science | |
| Outlet type | Medical and professional news |
| Population | Women |
| Source | Pharmacy Daily |
| URL | pharmacydaily.com.au/news/pbac-testosterone-knock-back-scientifically-and-logically-flawed/119377 (opens in a new tab) |
Specific Claim Evaluated
The Therapeutic Goods Administration approved a female-specific testosterone cream in 2020 for distressing low libido in postmenopausal women, and the manufacturer is seeking judicial review of the decision not to list it on the PBS.
Primary Research Supporting or Contradicting the Claim
Hypoactive sexual desire disorder in postmenopausal women is the only evidence-based indication for testosterone in women (Davis et al., 2019).
Corrected Evidence-Based Interpretation
The report is correct. The manufacturer's statements are advocacy and do not replace the committee's published reasoning.
Rationale for Grade
The article attributes criticism of the reimbursement decision to the manufacturer and reports the approved indication accurately.
References
- Davis SR, Baber R, Panay N, Bitzer J, Perez SC, Islam RM, Kaunitz AM, Kingsberg SA, Lambrinoudaki I, Liu J, Parish SJ, Pinkerton J, Rymer J, Simon JA, Vignozzi L, Wierman ME. Global consensus position statement on the use of testosterone therapy for women. J Clin Endocrinol Metab. 2019;104(10):4660-4666. PMID
Supporting excerpt: "The only evidence-based indication for testosterone for women is for HSDD."